Disease · MONDO_0002358

laryngeal carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. laryngeal carcinoma. Diseases, record MONDO_0002358. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002358

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: laryngeal carcinoma; Open Targets
Open Targets ID: MONDO_0002358; Open Targets
Other names: carcinoma of larynx, carcinoma of the larynx, larynx carcinoma; Open Targets
Disease Ontology: DOID:2600; Disease Ontology
NCI Thesaurus: C4855; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 3 of its 7 drugs, from ClinicalTrials.gov; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TORIPALIMAB	CHEMBL4297843	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ISOSORBIDE	CHEMBL1200660	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
HPPH	CHEMBL500853	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets17

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	1	Programmed cell death protein 1 antagonist	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
TUBA1A	Tubulin	1	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	1	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	1	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	1	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	1	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	1	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	1	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	1	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	1	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7280	Drugs and targets

1 to 10 of 17

See all 17 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01633541	Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer	Phase 2	55	2023-07-20	Laryngeal Cancer	CARBOPLATIN, CISPLATIN, DOCETAXEL, ISOSORBIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00169182	Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma	Phase 3	220		Larynx Cancer, Hypopharynx Cancer	CISPLATIN, DOCETAXEL, FLUOROURACIL	Its record names the disease	ClinicalTrials.gov
NCT05420597	Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma	Phase 2	61		Laryngeal Cancer, Hypopharyngeal Cancer	TORIPALIMAB	Its record names the disease	ClinicalTrials.gov
NCT04995120	Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma	Phase 2	42		Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms	CISPLATIN, DOCETAXEL, FLUOROURACIL, TORIPALIMAB	Its record names the disease	ClinicalTrials.gov
NCT00675233	Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx	Phase 1	29		Head and Neck Cancer	HPPH	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Platinum/Docetaxal + AT-101 vs Active Comparator Arm: deaths from any cause	1 of 36	1 of 18	54	NCT01633541	Trial comparisons
Platinum/Docetaxal + AT-101 vs Active Comparator Arm: serious adverse events	14 of 36	5 of 18	54	NCT01633541	Trial comparisons
Platinum/Docetaxal + AT-101 vs Active Comparator Arm: Number of Patients Alive and Free From Indication for Laryngectomy Three Months Post Treatment	27 of 34	12 of 18	52	NCT01633541	Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002358

GET https://conductscience.org/api/diseases/v1/MONDO_0002358/drugs

API reference For AI assistants